Retrospective Evaluation of Our Cases with Chronic Lymphocytic Leukemia: Single Centered Real Life Data.

Objectives: Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by clonal proliferation and accumulation of mature, typically CD5(+) B cells in peripheral blood, bone marrow, spleen and lymph nodes. We aimed to contribute to patient approach algorithms by examining the clinical and prognostic characteristics, treatment regimens used, treatment responses, that may be effective on survival of patients diagnosed with CLL who received follow-up and treatment in our center. Methods: The study included 152 patients, who were diagnosed with CLL between January 2011 and December 2021in the Hematology Clinic of Zonguldak Bulent Ecevit University Faculty of Medicine Hospital and whose data could be accessed. Treatment responses, survival status and factors affecting overall survival (OS) were evaluated retrospectively. Results: 152 patients (89 men, 63 women) were included in the study. The median age was 66.71±9.89 years. In our study, the survival of the patients in the group with advanced age, high LDH, high risk modified RAI and advanced Binnet was found to be low and statistically significant. The mean follow-up period in all our CLL cases was 53.44 months. During the follow-up period, 87 patients did not receive any treatment, while 65 patients received treatment. Five-year overall survival was 63.6%, and disease-free survival was found to be 59.3%. Conclusion: In CLL patients the appropriate treatment should be selected at the appropriate time, taking into account the characteristics of the patient and the disease. In order to achieve complete remission, effective chemo-immunotherapy agents should be started at the right time in patients. [ABSTRACT FROM AUTHOR]